Gain Therapeutics, Inc.

NASDAQ:GANX

Biotechnology

Healthcare
$1.18 +3.09%

+$0.06 today

Market cap
$50.33M
Beta
0.16
P/E (TTM)
-3.6
EPS (TTM)
-$0.50
52W Low $1.41High $4.34

Volume 4.26M

Average 0.64M

GANX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Gain Therapeutics, Inc.NASDAQ: GANX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $2.76M rose 22.4% year over year, ahead of the +1.7% change in trailing-twelve-month research & development. Sequentially, it rose 17.7% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +22.4% holds above the trailing-twelve-month pace of +1.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.76M+17.7% QoQ
Last fiscal yearDec 2025
$10.21M-5.4% YoY
LTMMar 2026
$10.72M+1.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.4%——
1 year-5.4%——
3-year CAGR+6.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
10.21M USD
Year-over-year change
-5.4%
4-year CAGR
+9.3%

Research & Development vs competitors

How GANX compares with its peers on the latest reported figures

  • GANX's LTM Mar 2026 research & development of $10.72M is the 6th highest of the 9 companies compared; the peer median is $35.53M.
  • Its year-over-year change of +1.7% is the 3rd highest of 8, against a peer median of -5.4%.
  • Over three fiscal years its annual growth of +6.8% compares with a peer median of +13.1%.
GANX Competitors Peer median
Research & Development for GANX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$16.37B +432309.4%+1606.6%—
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M -5.4%+24.0%1163.2%
ACETAdicet Bio, Inc.LTM Mar 2026$93.8M -4.5%+11.6%—
XBITXBiotech Inc.LTM Mar 2026$40.98M +3.6%+14.5%—
ADAGAdagene Inc.LTM Jun 2024$30.07M —-35.3%3686.7%
GANXGain Therapeutics, Inc.LTM Mar 2026$10.72M +1.7%+6.8%—
FBIOFortress Biotech, Inc.LTM Mar 2026$8.51M -76.4%-55.5%12.9%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$4.28M -18.5%-39.5%186.8%
NTRBNutriband Inc.LTM Apr 2026$1.45M -48.6%+24.4%80.7%
Peer median (excluding GANX) $35.53M-5.4%+13.1%186.8%

Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue164.99K140.11K55.18K00
Cost of Revenue00000
Gross Profit164.99K140.11K55.18K00
Gross Margin100.0%100.0%100.0%——
Research & Development7.16M8.38M11.52M10.79M10.21M
Selling, General & Admin6.83M9.54M10.79M9.56M8.5M
Operating Expenses13.99M17.92M22.31M20.35M18.71M
Depreciation & Amortization15.48K64.17K83.58K84.07K94.05K
EBITDA(13.87M)(17.43M)(22.1M)(19.79M)(19.21M)
EBITDA Margin-8407.0%-12443.0%-40059.2%——
Operating Income(13.83M)(17.78M)(22.25M)(20.35M)(18.71M)
Operating Margin-8379.8%-12688.1%-40328.3%——
Interest Income12.5K375.36K494.23K357.1K244.39K
Interest Expense00000
Other Income / Expenses(60.43K)279.28K64.89K476.22K(589.28K)
Income Before Tax(13.89M)(17.5M)(22.19M)(19.87M)(19.3M)
Pre-Tax Margin-8416.4%-12488.8%-40210.7%——
Income Tax Expense4.01K92.98K79.28K536.82K861.12K
Net Income(13.89M)(17.59M)(22.27M)(20.41M)(20.16M)
Net Margin-8418.9%-12555.1%-40354.3%——
EPS (Basic)(1.37)(1.48)(1.71)(0.89)(0.61)
EPS (Diluted)(1.37)(1.48)(1.71)(0.89)(0.61)
Weighted Avg Shares10.17M11.88M13.01M22.88M32.97M
Weighted Avg Shares (Diluted)10.17M11.88M13.01M22.88M32.97M

Gain Therapeutics, Inc.

NASDAQ:GANX

Intrinsic Alpha fair value

Locked

Current Price

$1.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.